PURPOSE: To characterize a tumor model containing a hypoxia-inducible reporter gene and to demonstrate utility by comparison of reporter gene expression to the uptake and distribution of the hypoxia tracer (18)F-fluoromisonidazole ((18)F-FMISO). METHODS: Three tumors derived from the rat prostate cancer cell line R3327-AT were grown in each of two rats as follows: (1) parental R3327-AT, (2) positive control R3327-AT/PC in which the HSV1-tkeGFP fusion reporter gene was expressed constitutively, (3) R3327-AT/HRE in which the reporter gene was placed under the control of a hypoxia-inducible factor-responsive promoter sequence (HRE). Animals were coadministered a hypoxia-specific marker (pimonidazole) and the reporter gene probe (124)I-2'-fluoro-2'-deoxy-1-beta-d-arabinofuranosyl-5-iodouracil ((124)I-FIAU) 3 h prior to sacrifice. Statistical analysis of the spatial association between (124)I-FIAU uptake and pimonidazole fluorescent staining intensity was then performed on a pixel-by-pixel basis. Utility of this system was demonstrated by assessment of reporter gene expression versus the exogenous hypoxia probe (18)F-FMISO. Two rats, each bearing a single R3327-AT/HRE tumor, were injected with (124)I-FIAU (3 h before sacrifice) and (18)F-FMISO (2 h before sacrifice). Statistical analysis of the spatial association between (18)F-FMISO and (124)I-FIAU on a pixel-by-pixel basis was performed. RESULTS: Correlation coefficients between (124)I-FIAU uptake and pimonidazole staining intensity were: 0.11 in R3327-AT tumors, -0.66 in R3327-AT/PC and 0.76 in R3327-AT/HRE, confirming that only in the R3327-AT/HRE tumor was HSV1-tkeGFP gene expression associated with hypoxia. Correlation coefficients between (18)F-FMISO and (124)I-FIAU uptakes in R3327-AT/HRE tumors were r=0.56, demonstrating good spatial correspondence between the two tracers. CONCLUSIONS: We have confirmed hypoxia-specific expression of the HSV1-tkeGFP fusion gene in the R3327-AT/HRE tumor model and demonstrated the utility of this model for the evaluation of radiolabeled hypoxia tracers.
PURPOSE: To characterize a tumor model containing a hypoxia-inducible reporter gene and to demonstrate utility by comparison of reporter gene expression to the uptake and distribution of the hypoxia tracer (18)F-fluoromisonidazole ((18)F-FMISO). METHODS: Three tumors derived from the ratprostate cancer cell line R3327-AT were grown in each of two rats as follows: (1) parental R3327-AT, (2) positive control R3327-AT/PC in which the HSV1-tkeGFP fusion reporter gene was expressed constitutively, (3) R3327-AT/HRE in which the reporter gene was placed under the control of a hypoxia-inducible factor-responsive promoter sequence (HRE). Animals were coadministered a hypoxia-specific marker (pimonidazole) and the reporter gene probe (124)I-2'-fluoro-2'-deoxy-1-beta-d-arabinofuranosyl-5-iodouracil ((124)I-FIAU) 3 h prior to sacrifice. Statistical analysis of the spatial association between (124)I-FIAU uptake and pimonidazole fluorescent staining intensity was then performed on a pixel-by-pixel basis. Utility of this system was demonstrated by assessment of reporter gene expression versus the exogenous hypoxia probe (18)F-FMISO. Two rats, each bearing a single R3327-AT/HRE tumor, were injected with (124)I-FIAU (3 h before sacrifice) and (18)F-FMISO (2 h before sacrifice). Statistical analysis of the spatial association between (18)F-FMISO and (124)I-FIAU on a pixel-by-pixel basis was performed. RESULTS: Correlation coefficients between (124)I-FIAU uptake and pimonidazole staining intensity were: 0.11 in R3327-AT tumors, -0.66 in R3327-AT/PC and 0.76 in R3327-AT/HRE, confirming that only in the R3327-AT/HRE tumor was HSV1-tkeGFP gene expression associated with hypoxia. Correlation coefficients between (18)F-FMISO and (124)I-FIAU uptakes in R3327-AT/HRE tumors were r=0.56, demonstrating good spatial correspondence between the two tracers. CONCLUSIONS: We have confirmed hypoxia-specific expression of the HSV1-tkeGFP fusion gene in the R3327-AT/HRE tumor model and demonstrated the utility of this model for the evaluation of radiolabeled hypoxia tracers.
Authors: Esther G C Troost; Peter Laverman; Mariëlle E P Philippens; Jasper Lok; Albert J van der Kogel; Wim J G Oyen; Otto C Boerman; Johannes H A M Kaanders; Johan Bussink Journal: Eur J Nucl Med Mol Imaging Date: 2008-04-18 Impact factor: 9.236
Authors: G V Martin; J H Caldwell; M M Graham; J R Grierson; K Kroll; M J Cowan; T K Lewellen; J S Rasey; J J Casciari; K A Krohn Journal: J Nucl Med Date: 1992-12 Impact factor: 10.057
Authors: Anna S E Ljungkvist; Johan Bussink; Paulus F J W Rijken; Johannes H A M Kaanders; Albert J van der Kogel; Juliana Denekamp Journal: Int J Radiat Oncol Biol Phys Date: 2002-09-01 Impact factor: 7.038
Authors: J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn Journal: Eur J Nucl Med Mol Imaging Date: 2003-03-11 Impact factor: 9.236
Authors: Pat Zanzonico; Joseph O'Donoghue; J Donald Chapman; Richard Schneider; Shangde Cai; Steven Larson; Bixiu Wen; Yuchun Chen; Ronald Finn; Shutian Ruan; Leo Gerweck; John Humm; Clifton Ling Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-02 Impact factor: 9.236
Authors: K I Wijffels; J H Kaanders; P F Rijken; J Bussink; F J van den Hoogen; H A Marres; P C de Wilde; J A Raleigh; A J van der Kogel Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: Keisha C McCall; John L Humm; Rachel Bartlett; Megan Reese; Sean Carlin Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-23 Impact factor: 7.038
Authors: Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin Journal: NMR Biomed Date: 2012-07-08 Impact factor: 4.044
Authors: Marian Axente; Jun He; Christopher P Bass; Jerry I Hirsch; Gobalakrishnan Sundaresan; Jeffrey Williamson; Jamal Zweit; Andrei Pugachev Journal: Radiother Oncol Date: 2012-03-21 Impact factor: 6.280
Authors: Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy Journal: Radiother Oncol Date: 2017-12-19 Impact factor: 6.280
Authors: Rachel M Bartlett; Bradley J Beattie; Manoj Naryanan; Jens-Christoph Georgi; Qing Chen; Sean D Carlin; Gordon Roble; Pat B Zanzonico; Mithat Gonen; Joseph O'Donoghue; Alexander Fischer; John L Humm Journal: J Nucl Med Date: 2012-08-29 Impact factor: 10.057
Authors: Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; Estefanía Martino-Echarri; Carlos Peris-Torres; María Del Carmen Plaza-Calonge; Juan Carlos Rodríguez-Manzaneque Journal: Oncotarget Date: 2016-06-07
Authors: Elliot H Akama-Garren; Nikhil S Joshi; Tuomas Tammela; Gregory P Chang; Bethany L Wagner; Da-Yae Lee; William M Rideout; Thales Papagiannakopoulos; Wen Xue; Tyler Jacks Journal: Sci Rep Date: 2016-02-18 Impact factor: 4.379